Trials / Recruiting
RecruitingNCT06187402
A Study of LM-24C5 For Advanced Solid Tumors
A Phase I/II, First-in-Human (FIH), Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM-24C5 in Patients With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 49 (estimated)
- Sponsor
- LaNova Medicines Limited · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-24C5 in subjects with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LM-24C5 | Administered intravenously |
Timeline
- Start date
- 2023-12-20
- Primary completion
- 2026-06-30
- Completion
- 2026-12-30
- First posted
- 2024-01-02
- Last updated
- 2025-09-09
Locations
6 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06187402. Inclusion in this directory is not an endorsement.